Skip to main content
Industry Insights

Industry Insights · Industry Bulletin Digest

Polymer Medical Device Bulletin 2025 Issue 3 digest: procurement changes and EU exports

Procurement rules and export pace were the device industry's top two concerns in 2025; this issue signals both.

Published:2025-09-30Updated:2025-09-30

Updated
Illustration of Polymer Medical Device Bulletin 2025 Issue 3 highlights
Bulletin 2025 Issue 3 highlights: procurement's 'eight changes', H1 EU exports over USD 5B, two-Asias exports, the adverse-event report. Illustrative; content per the public bulletin.
In short: Citable points from Issue 3: national procurement saw 'eight changes', no longer anchored to the 'lowest price' — a key signal of rule optimization; on exports, H1 2025 EU device exports topped USD 5B with 10%+ growth to several countries, plus a status/outlook report for South and Southeast Asia ('the two Asias'); on regulation, the 2024 adverse-event annual report and 2024 regulatory statistics, plus export sales certificates, classification adjustments, online-sales quality inspections and the registration self-test guide.

Procurement: beyond lowest price

This issue records 'national procurement's eight changes, no longer anchored to lowest price', reflecting a shift from 'lowest price only' to broader quality and supply-stability considerations — with real impact on pricing and product strategy.

Exports: EU and the two Asias

  • H1 2025 EU device exports topped USD 5B, with 10%+ growth to several countries;
  • a status and outlook report for South and Southeast Asia;
  • regional diversification as a hedge against single-market risk.

Regulation and quality

It releases the 2024 adverse-event annual report and regulatory statistics, and covers export sales certificate management, classification adjustments, online-sales quality on-site inspection and the registration self-test guide — helping firms grasp compliance.

The BIO angle

Procurement 'no longer only lowest price' raises the weight of quality and supply stability — favoring high-end materials known for stable compliance. With traceable, well-documented silicone supply, BIO helps customers stay steady through procurement and globalization.

FAQ

What's the core of procurement's 'eight changes'?

The direction moves beyond anchoring to 'lowest price', weighing quality and supply stability more — a rule-optimization signal.

How big were H1 2025 EU exports?

Over USD 5B, with 10%+ growth to several countries; the EU is a key growth market.

What are 'the two Asias'?

South Asia and Southeast Asia — emerging regional markets where China's device exports grow fast.

Related reading

Browse all insights →

Note: an original analysis compiled from public industry information; figures and conclusions per official/original sources. Not investment advice.

Building in China's medical-device market?

From advanced medical silicone/polymers to material selection, regulatory and supply, BIO helps global and local partners move from selection to landed supply in China.